๐
Cerezyme
imiglucerase
Malattia di Gaucher
โ
Autorizzato
โ
Nessun allarme attivo
Questo medicinale non presenta carenze in corso, lettere di sicurezza o richiami.
A cosa serve
Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions: anaemia after exclusion of other causes, such as iron deficiency Thrombocytopenia Bone disease after exclusion of other causes such as Vitamin D deficiency hepatomegaly or splenomegaly
โ ๏ธ Sicurezza del paziente
No
๐ Avvisi passati (2)
Pagina ufficiale EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme